Autoimmune Addison's disease (AAD) is often associated with other components in autoimmune polyendocrine syndromes (APS). Whereas APS I is caused by mutations in the AIRE gene, the susceptibility genes for AAD and APS II are unclear. In the present study, we investigated whether polymorphisms or copy number variations in the AIRE gene were associated with AAD and APS II. First, nine SNPs in the AIRE gene were analyzed in 311 patients with AAD and APS II and 521 healthy controls, identifying no associated risk. Second, in a subgroup of 25 of these patients, AIRE sequencing revealed three novel polymorphisms. Finally, the AIRE copy number was determined by duplex quantitative PCR in 14 patients with APS I, 161 patients with AAD and APS II and in 39 healthy subjects. In two Scandinavian APS I patients previously reported to be homozygous for common AIRE mutations, we identified large deletions of the AIRE gene covering at least exon 2 to exon 8. We conclude that polymorphisms in the AIRE gene are not associated with AAD and APS II. We further suggest that DNA analysis of the parents of patients found to be homozygous for mutations in AIRE, always should be performed.
Introduction
Autoimmunity is the most common cause of primary adrenal failure (autoimmune Addison's disease (AAD)) in Western countries. It affects women more often than men, but can commence at virtually any age. A hallmark of AAD is the preponderance of multiorgan autoimmunity, most commonly as part of an autoimmune polyendocrine syndrome type II (APS II), that is, the combination of AAD with autoimmune thyroid disease and/or type 1 diabetes. It is assumed that both genetic and environmental factors contribute to the risk of developing AAD, similar to the situation in type 1 diabetes and many other autoimmune diseases. Several genes and genetic regions have been associated with AAD, notably the major histocompatibility complex (MCH), and the genes encoding the cytotoxic T lymphocyte antigen 4 (CTLA-4) [1] [2] [3] and protein tyrosine phosphatase non-receptor 22 (PTNP22). 4 Particularly strong association to the MHC class 2 haplotypes DR3-DQ2, DR4-DQ8 [5] [6] [7] [8] and to MHC class I chain-related A (MICA) 6, 9 have been noted, but other genes are probably also involved. However, owing to the rarity of AAD, many studies have been underpowered and therefore clear associations have been difficult to identify.
Autoimmune polyendocrine syndrome type I (APS I) is an even rarer disease, 10, 11 typically presenting with the major clinical manifestations chronic mucocutanous candidiasis, primary hypoparathyroidism and AAD. 12 APS I is caused by mutations in the autoimmune regulator (AIRE) gene, encoding the transcription factor AIRE that regulates expression of organ-specific transcripts in thymic medullary epithelial cells. Thereby, AIRE regulates negative selection of autoreactive thymocytes. 13 Thus polymorphisms or other variations in AIRE could potentially contribute, together with other genes, to autoimmunity in other and more common autoimmune diseases. 14, 15 However, so far no strong evidence has been presented to substantiate this in humans, neither studies searching for mutations in the AIRE gene, or in single nucleotide polymorphism (SNP) analyses of the AIRE gene region. 16, 17 Since AAD is one of the main manifestations of APS I, we asked whether common and/or rare genetic variants in AIRE are associated with AAD.
Subjects and methods

Subjects
Patients were recruited to the Norwegian Addison Registry by contacting departments of internal medicine and endocrinology at all hospitals in Norway. A search of the records of each hospital was performed using ICD-8-10 codes. Altogether 311 patients with confirmed Addison's disease were recruited to the study. The diagnosis of AAD was based on typical biochemical findings as low morning serum cortisol concentration (o150 nmol l
À1
) and simultaneously high level of ACTH (420 pmol l
). 18 Among those recruited, 25 patients with Addison's disease and APS I-like features were selected for sequencing of the AIRE gene on the basis of one of the following criteria; Addison's disease diagnosed at o20 years of age, autoantibodies against tryptophan hydroxylase (TPH-1), tyrosin hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), side-chain cleavage enzyme (SCC) or 17a-hydroxylase (17OH) and the presence of ectodermal manifestations associated with APS I. Previously, these patients had been screened for the most common Norwegian AIRE mutations, which identified one patient with mutations in the AIRE gene. 19 In this study, all the exons and flanking introns of the AIRE gene were sequenced. Blood from 521 healthy individuals were collected as normal controls. DNA from 161 AAD patients, 14 patients with APS I and 39 healthy blood donors were examined for AIRE copy numbers. Thirteen of these Norwegian patients had previously been characterized as homozygous for a mutation in the AIRE gene while no mutations had been found in one patient. 20 One Danish female with APS I (AAD, hypoparathyroidism, ovarial insufficiency, keratitis, bilateral ptosis, nail pitting and alopecia), which previously had been genotyped homozygous for the Finnish major mutation (c.769C4T) in AIRE, was also included in the AIRE copy number analysis.
Assay of antibodies
Antibodies against SCC, 17OH, AADC, TPH-1 and TH were assayed by a method based on the in vitro transcribed and translated protein as described by Ekwall et al. 21 Interferon antibodies were determined in the 25 APS I-like patients which were AIRE sequenced as described by Meager et al. 22 by enzyme-linked immunosorbent assay (ELISA) and human cell line-based bioassay for neutralization of type I IFN activity as described previously.
Mutational analysis of the AIRE gene DNA was extracted from 3-10 ml of patient EDTA blood samples according to standard protocols. All 14 exons of the AIRE gene (EMBL accession number AJ009610) were amplified by PCR and sequenced using primers and conditions as described previously. 20 SNP-analysis of AIRE Nine SNPs in AIRE (rs878081, rs1800520, rs933150, rs2776377, rs2073610, rs2256817, rs2850167, rs760426, rs2075876) were chosen based on a previous association study examining AIRE SNPs in patients with type 1 diabetes 16 and Hap Map data in an attempt to tag all common variations in the AIRE gene. All primers and probes are commercially available (Applied Biosystems). The Taqman allelic discrimination assay was performed essentially as described by the manufacturer (Applied Biosystems), although we used less volume of the reagents than recommended. Briefly, 2 ml of patient or control DNA (concentration 5-50 ng ml
À1
) were applied into wells of a 384-well optical readable plate. The DNA was allowed to dry at room temperature over night. A THEONYX robot (Aviso, Greiz-Gommla, Germany) was used to aliquot 2 ml of Taqman mastermix including primers and probes into each well of the plate. Negative controls (water) and positive controls (known genotype, run on several plates) were included. The samples were analyzed on the ABI 7900HT Genetic Analyzer and SDS 2.1/2.2 software (Applied Biosystems).
AIRE copy number (copy number variation (CNV assay))
The analysis was performed by running a duplex Taqman real-time PCR assay. For every sample, the fluorescent signals from the target gene, AIRE and from the reference gene, Rb-1 (Retinoblastoma-1, retinoblastoma susceptibility protein), 23 were detected using different probes. The reference gene is known to be available in two copies in the genome. Using a standard curve for each gene, the number of AIRE-copies can be calculated as the relative relationship between the signal from AIRE and the signal from the Rb-1-gene. The assay mixture consisted of (for a 10 ml reaction) 5 ml (2 Â ) Taqman universal PCR mastermix, 0.1 ml of Amplitaq Gold, 2.5 ml of dH 2 O, 0.7 ml of Rb-1 primer/probe mastermix (22.5 mM primers and 5 mM probe), 0.7 ml of AIRE-1 primer/probe mastermix (5.63 mM primers and 1.25 mM probe, primers/probe No 1, Table 1 )) and 15 ng DNA (1 ml). Most samples were run in duplicates. Primers and probes were designed by Beacon Designer v. 2.1 (Premier Biosoft International) ( Table 1 ). All reagents were purchased from Applied Biosystems.
Aberrant copy number findings were verified by a Taqman real-time PCR duplex assay using primers and probes at different locations in AIRE (primers/probe No 2-6, see Table 1 ), and by using another reference gene (peripheral myelin protein 22, PMP22). In one of the cases (N1), samples from the parents and four siblings were obtained and analyzed to confirm our findings in the offspring.
Genetic analysis and statistics
Haplotype mapping (Hap Map) data was used to tag all known variation with a 5% minor allele frequency, with the pairwise tagging method and cutoff and r 2 X0.8 using the Haploview software. 24 Single point analysis and haplotype estimations were performed using Haploview and Unphased software. 25 P-values presented are not corrected for the number of tests performed. Figure 1 shows the positions of the nine chosen AIRE-SNPs. The pattern of LD in the Norwegian samples was similar to Hap Map data and shows that the SNPs identify most of the common variation in the region. The genotype frequencies of all variants tested were consistent with Hardy-Weinberg equilibrium. The allele frequencies of the 9 AIRE polymorphisms are described in Table 2 . None of the polymorphisms were associated with AAD (Table 2) . Finally, exploratory haplotype analyses did not reveal any haplotype associations in the region.
Results
Frequency of known AIRE polymorphisms in Norwegian Addison patients
Novel AIRE mutations and polymorphisms in patients with APS-I-like features Three novel polymorphisms of AIRE were identified by sequencing all 14 exons of the AIRE gene in 25 patients with APS I-like features. Two out of 25 patients were heterozygous for a C to T transition in codon 1411 predicting an arginine to a cysteine substitution (c.1411C4T, p.Arg471Cys). One patient had a sequence variant in codon 1507, changing Asp to Asn (c.1507G4A, p.Asp503Asn). Yet another patient exhibited a synonymous SNP in codon 1476 (c.1476C4T, p.Pro492Pro).
We then genotyped all our Addison's disease patients (n ¼ 311) and 200 healthy DNA donors for the c.1411C4T and c.1507G4A polymorphisms. The silent mutation c.1476 was not considered to be pathogenic. In addition, we analyzed the frequency of another previously identified polymorphism (c.901G4A, p.Val301Met). This polymorphism was previously found in one Norwegian patient with AAD, autoimmune thyroiditis, premature menopause and autoantibodies towards AADC. 27 Four healthy blood donors (N ¼ 107) proved to be heterozygous for c.1411C4T while two AAD patients (N ¼ 302) and one healthy donor (N ¼ 197) were heterozygous for c.1507G4A. Hence, these SNPs are unlikely to cause an APS I-like phenotype in a heterozygous state. However, no healthy individual (N ¼ 197) carried the c.901G4A variant. The results are summarized in Table 3 .
AIRE copy number (CNV assay)
None of the 161 patients with AAD nor 39 controls showed CNV for intron 2. However, two out of 14 analyzed APS I patients were positive for this variant. The existence of the deletion was confirmed also for the exon 2 and intron 7 CNV assays. The same AIRE gene deletion was detected in the mother and two of the siblings of one of the patients (N1). PCR amplification of exon 8 from both patients and family members of N1 followed by visualization of the product on an agarose gel revealed that the deletion was present also in exon 8. In the CNV assay, the AIRE deletion ratio varied from 0.48 to 0.53 whereas the AIRE ratio in normal controls ranged from 0.88 to 1.14 (mean 1.04).
To identify the outer boundaries of these deletions, we confirmed that both the patients (N1 and D2) and the mother of patient N1 (N1m) were negative for CNV in exon 14 and that N1m was heterozygous for marker rs933150 in intron 9. Furthermore, patient N1 was heterozygous for the D21s1912 microsatellite marker located about 130 kb upstream the gene. In addition, we performed CNV analyses for exon 1 and intron 8, which revealed that patient N1 lacks also these regions in one allele. Hence, the deletion of patient N1 span at least exon 1 to intron 8, but does not start before 130 kb upstream the AIRE gene, and does not proceed into intron 9 ( Figure 2 ). The deletion of patient D2 also span exon 2 to exon 8, but not into exon 14. We were unable to obtain more information on the deletion in this patient.
Interferon autoantibodies
The APS I-like patients who were screened for mutations in AIRE using sequencing were analyzed for autoantibodies against type I interferons. None of the 25 patients had neutralizing autoantibodies against IFNo or IFNa2 (data not shown). 
Discussion
We show here that two Scandinavian APS I patients, previously decided to be homozygous for common AIRE mutations, have large deletions in one AIRE-allele with a concomitant disease-causing mutation. The gross deletion covers at least the region from exon 2 to exon 8, but does not extend into intron 9 (in one of the patients). The Norwegian APS I cohort comprises 16 patients (three of which are siblings) who have previously been characterized as homozygous for different mutations in AIRE. 20 However, the number of AIRE alleles has not been examined previously. Standard mutational screening techniques with PCR-amplification followed by sequencing of the amplified product fail to detect the number of copies of the specified region. On the webpage for 'Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff' http://www.hgmd.cf.ac.uk/ac/all.php only two big deletions of AIRE are listed (IVS1_IVS4, 1734 bp intron 1-exon 4 28 and c.191_226del36 in exon 2 29 ). The deletions reported here are the largest deletions that have been reported in this gene. To avoid this pitfall of misdiagnosis, DNA analysis of the parents of patients found to be homozygous should be included. Moreover, we suggest that copy number analysis should be performed when AIRE sequence analysis in patients with typical clinical features of APS I fails to detect genetic abnormalities. A large deletion of the AIRE gene in one allele, which coexists with a mutation on a different site of the gene in the other allele, will appear as a heterozygous mutation when performing standard sequence analysis. The correct diagnosis in this situation is a homozygous defect of the gene and the result will probably be APS I for the patient. The importance of diagnosing APS I early has been pinpointed by us and others in the past. 20 In this paper, we also show results, which indicate that common polymorphisms in AIRE do not influence susceptibility to develop AAD in the Norwegian population, at least not as a single factor. Furthermore, by sequencing of the AIRE gene in an additional 25 patients with AAD, no non-synonymous polymorphisms, except possibly the Val301Met transition, seem to have pronounced impact on the risk of developing ADD. In a previous study by Ferrera et al., 30 this mutation was found in a female patient with systemic sclerosis who was affected by autoimmune thyroiditis. The same SNP was also found in a few patients with alopecia, however in the same frequencies as in healthy controls. 31 The Val/Met variant changes an amino acid in the ubiquitin ligase region of the protein and may have functional consequences, perhaps in histone binding. 32, 33 Furthermore, the number of patients with this polymorphism is low, which makes it unlikely that it impacts on the susceptibility to develop AAD. We also considered the possibility that this variation had a dominant negative effect as has previously been described for another mutation in one family with APS I. 34, 35 However, parents of both patients were healthy, which indicates that this is not the case. It is interesting to note that a single mutation affecting a nearby amino acid residue, that is, Arg303Pro, was recently found in a Polish APS I patient. No other mutation was identified in this patient, and the parents were healthy. 36 Ideally, functional studies in model systems should be done to fully exclude the involvement of this polymorphism in the risk of developing AAD.
Previously, two studies have succeeded in linking variations in AIRE to different diseases than APS I. A role for the intronic variant G11107A in the risk of developing systemic sclerosis in combination with thyroiditis was recently suggested. 30 However, few subjects were included in the study and the results need to be replicated before a firm conclusion could be drawn. The Ser278Arg mutation was found to be associated with alopecia in a recent study on 202 patients and 175 controls. 31 The results should be verified in other ethnic cohorts. Three studies, examining the prevalence of the common 13 bp deletion in exon 8 of AIRE (known to cause APS I) failed to show an association in patients with Addison's disease, Graves' disease, type 1 diabetes and hypothyroidism. 1, 37, 38 Another study did not find APS I-related AIRE gene mutations in patients with sporadic idiopathic hypoparathyroidism. 39 Moreover, Figure 2 A schematic figure of the large deletion in the two APS I patients N1 (Norwegian patient) and D2 (Danish patient). The deletion spans from exon 2 until exon 8, but does not go beyond the end of intron 9 (confirmed for patient N1). The presence of exon 1, exon 2, intron 2, intron 7, intron 8 and exon 14 was assayed by quantitative PCR to calculate CNV. The presence of the 5 0 and 3 0 ends of the AIRE gene were assessed using the microsatelite polymorphism markers D21s1912 (about 130 kb upstream of AIRE), D21s1979, D21s400 and D21s171 (performed on patient N1 and family). SNP rs933150 was used for allelic discrimination and is located in intron 9. No info means that the markers could not discriminate between one or two AIRE alleles. D2* and the * mark in the figure denote that there are no info for exon 1 and intron 8 for patient D2. data on 733 type I diabetes patients and 705 vitiligo patients showed no association to the AIRE locus in two recent studies. 16, 17 It is also interesting to note that no one has systematically studied carriers of pathogenic AIRE mutations (relatives of APS I patients) for their susceptibility to pathological autoimmunity compared to controls with two healthy AIRE alleles. Such studies have been performed in mice, which have revealed a doselimiting role of AIRE in organ-specific autoimmunity. 14 The same mechanism has been suggested, but not shown to play a role in humans. 40 The genes so far confirmed to be associated with autoimmune Addison's disease do not explain all the genetic contribution to Addison's disease. Although our results suggest that genetic variation in the AIRE gene does not seem to affect the risk of developing AAD in Norwegian patients, ideally it should be replicated in other ethnic groups. The possibility that dysregulation of AIRE epigenetics is involved in AAD development should also be tested. However, given the fact that neither studies of patients with AAD nor type I diabetes have shown an association between common variation in the AIRE locus and autoimmunity, together with the knowledge that AAD and type I diabetes are common manifestations of APS I, AIRE might not be a likely candidate gene for other autoimmune conditions. However, we cannot rule out that these SNPs work in combination with other genetic factors to contribute to autoimmunity.
The presence of neutralizing autoantibodies against IFNo is the most specific and sensitive indicator of APS I. 20, 22 We have previously shown that patients with Addison's disease or APS II may exhibit low/moderate titers of binding autoantibodies against IFNa2 and IFNo, but these autoantibodies do not neutralize the activity of the cytokines in vitro. 20 The failure to detect these antibodies in APS I-like patients, supports our conclusion that none of these patients have APS I. These findings give even further evidence that patients who present with a clinical picture reminiscent of APS I should be screened for neutralizing autoantibodies against type I IFN before mutational analysis of the AIRE gene is performed.
In conclusion, AIRE is probably not involved as a susceptibility gene for Addison's disease. Our findings of large deletions in the AIRE locus in two patients should prompt AIRE copy number analysis in patients with typical clinical findings without AIRE mutations.
